These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 23669338

  • 1. Effect of cyclosporine on lymphocytic variant hypereosinophilic syndrome.
    Tabata R, Tabata C, Katashima Y, Yasumizu R.
    Int Immunopharmacol; 2013 Aug; 16(4):488-91. PubMed ID: 23669338
    [Abstract] [Full Text] [Related]

  • 2. The proportion of CD3- CD4+ T-cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L-HES).
    Helbig G, Wichary R, Razny M, Rodzaj M, Wozniczka K, Dziaczkowska-Suszek J, Kyrcz-Krzemien S.
    Scand J Immunol; 2010 Oct; 72(4):372-3. PubMed ID: 20883323
    [No Abstract] [Full Text] [Related]

  • 3. Successful treatment of hypereosinophilic syndrome with cyclosporine.
    Donald CE, Kahn MJ.
    Am J Med Sci; 2009 Jan; 337(1):65-6. PubMed ID: 19002011
    [Abstract] [Full Text] [Related]

  • 4. [Hypereosinophilic syndrome with DIC treated successfully with a combination of high-dose methylprednisolone and cyclosporin A].
    Fukuta A, Hara T, Tsurumi H, Moriwaki H.
    Rinsho Ketsueki; 2001 Nov; 42(11):1145-7. PubMed ID: 11808087
    [Abstract] [Full Text] [Related]

  • 5. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
    Roufosse F, de Lavareille A, Schandené L, Cogan E, Georgelas A, Wagner L, Xi L, Raffeld M, Goldman M, Gleich GJ, Klion A.
    J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
    [Abstract] [Full Text] [Related]

  • 6. [Successful treatment of hypereosinophilic syndrome with cyclosporin and steroids].
    Akiyama Y, Shimizu A, Kimura A, Onodera R, Minatani M, Horikoshi K, Jingu K, Fukakusa M, Kotajima F, Sato T.
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 May; 35(5):541-5. PubMed ID: 9234632
    [Abstract] [Full Text] [Related]

  • 7. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
    Williams AK, Dou C, Chen LYC.
    Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
    [Abstract] [Full Text] [Related]

  • 8. New diagnostic tool for differentiation of idiopathic hypereosinophilic syndrome (HES) and secondary eosinophilic states.
    Berki T, Dávid M, Bóné B, Losonczy H, Vass J, Németh P.
    Pathol Oncol Res; 2001 Dec; 7(4):292-7. PubMed ID: 11882909
    [Abstract] [Full Text] [Related]

  • 9. Eosinophils affect functions of in vitro-activated human CD3-CD4+ T cells.
    Harfi I, Schandené L, Dremier S, Roufosse F.
    J Transl Med; 2013 May 06; 11():112. PubMed ID: 23642304
    [Abstract] [Full Text] [Related]

  • 10. An 8-year-old boy with hypereosinophilic syndrome.
    Hosoki K, Nagao M, Iguchi K, Ihara T, Yamada Y, Higashigawa M, Kephart GM, Kita H, Fujisawa T.
    Int Arch Allergy Immunol; 2011 May 06; 155 Suppl 1():117-22. PubMed ID: 21646806
    [Abstract] [Full Text] [Related]

  • 11. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis.
    Ahn JK, Seo JM, Yu J, Oh FS, Chung H, Yu HG.
    Invest Ophthalmol Vis Sci; 2005 Jul 06; 46(7):2458-64. PubMed ID: 15980236
    [Abstract] [Full Text] [Related]

  • 12. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
    Kim YJ, Prussin C, Martin B, Law MA, Haverty TP, Nutman TB, Klion AD.
    J Allergy Clin Immunol; 2004 Dec 06; 114(6):1449-55. PubMed ID: 15577851
    [Abstract] [Full Text] [Related]

  • 13. IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: A comparative case series.
    Carruthers MN, Park S, Slack GW, Dalal BI, Skinnider BF, Schaeffer DF, Dutz JP, Law JK, Donnellan F, Marquez V, Seidman M, Wong PC, Mattman A, Chen LY.
    Eur J Haematol; 2017 Apr 06; 98(4):378-387. PubMed ID: 28005278
    [Abstract] [Full Text] [Related]

  • 14. In vivo expression of IL-4, IL-5, IL-13 and IFN-gamma mRNAs in peripheral blood mononuclear cells and effect of cyclosporin A in a patient with Kimura's disease.
    Katagiri K, Itami S, Hatano Y, Yamaguchi T, Takayasu S.
    Br J Dermatol; 1997 Dec 06; 137(6):972-7. PubMed ID: 9470918
    [Abstract] [Full Text] [Related]

  • 15. Selective priming of peripheral blood eosinophils in patients with idiopathic hypereosinophilic syndrome.
    Lampinen M, Oberg G, Venge P, Carlson M.
    APMIS; 2006 Nov 06; 114(11):757-63. PubMed ID: 17078855
    [Abstract] [Full Text] [Related]

  • 16. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB, Sheikh J, Singh A.
    Curr Med Res Opin; 2010 Aug 06; 26(8):1933-46. PubMed ID: 20565230
    [Abstract] [Full Text] [Related]

  • 17. Hypereosinophilic syndrome: progression of peripheral neuropathy despite controlled eosinophil levels.
    Cengiz B, Sucak G, Kuruoğlu R, Tan E.
    Acta Neurol Belg; 1999 Jun 06; 99(2):133-7. PubMed ID: 10427356
    [Abstract] [Full Text] [Related]

  • 18. Hypereosinophilic syndrome: case presentation and update.
    Leiferman KM, Gleich GJ.
    J Allergy Clin Immunol; 2004 Jan 06; 113(1):50-8. PubMed ID: 14713907
    [Abstract] [Full Text] [Related]

  • 19. Hypereosinophilic syndromes.
    Roufosse FE, Goldman M, Cogan E.
    Orphanet J Rare Dis; 2007 Sep 11; 2():37. PubMed ID: 17848188
    [Abstract] [Full Text] [Related]

  • 20. Lymphocytic variant of hypereosinophilic syndrome.
    Zaheri S, Alam A, Marks AJ, Wakelin S.
    Clin Exp Dermatol; 2010 Aug 11; 35(6):634-6. PubMed ID: 20236287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.